TY - JOUR
T1 - Emerging nanotherapeutic strategies in breast cancer
AU - Blanco, Elvin
AU - Ferrari, Mauro
N1 - Funding Information:
The authors are grateful to Francisca E. Cara and Carlos A. Gonzalez for their assistance in manuscript preparation. Matthew G. Landry is acknowledged for preparation of manuscript schematics. The authors appreciate the support of a CDMRP Department of Defense Breast Cancer Research Program (DOD/BCRP) Innovator Award (grant number W81XWH-09-1-0212 ) awarded to MF. EB is grateful to the DOD/BCRP (grant number W81XWH-11-1-0103 ) and the Susan G. Komen Breast Cancer Foundation (grant number KG101394 ) for postdoctoral fellowships.
PY - 2014/2
Y1 - 2014/2
N2 - Nanoparticle-based drug delivery platforms are emerging as powerful chemotherapeutic modalities in breast cancer. Doxorubicin and paclitaxel nanoparticle formulations are currently used clinically, yielding distinct pharmacokinetic parameters that prolong blood circulation times, enhance drug accumulation in tumors, and limit adverse side effects to patients. And while these nanoconstructs have shown substantial improvements in patient tolerability and survival, several emerging trends stand to make a significant impact on future generations of nanoparticle platforms for breast cancer therapy. Firstly, there is a heightened understanding of several processes involved in tumor growth, potentiation, and invasion, resulting in the identification of several attractive molecular targets. This in turn has given rise to antibody-based therapeutics, drug repositioning, and the burgeoning field of RNA interference (RNAi). Secondly, an enhanced understanding of transport phenomena involved in delivery of chemotherapeutics has led to a rethinking and retooling of nanoscale drug carrier designs. Nanoparticle platforms are now incorporating features meant to overcome biological barriers and enhance drug accumulation within tumors, all the while incorporating unique chemistries that enable for controlled release of therapeutic payloads. This review aims to detail the current clinical state of nanoparticle-based therapeutics in breast cancer, as well as highlight several platforms that exemplify the future generation of innovative approaches to chemotherapy in breast cancer.
AB - Nanoparticle-based drug delivery platforms are emerging as powerful chemotherapeutic modalities in breast cancer. Doxorubicin and paclitaxel nanoparticle formulations are currently used clinically, yielding distinct pharmacokinetic parameters that prolong blood circulation times, enhance drug accumulation in tumors, and limit adverse side effects to patients. And while these nanoconstructs have shown substantial improvements in patient tolerability and survival, several emerging trends stand to make a significant impact on future generations of nanoparticle platforms for breast cancer therapy. Firstly, there is a heightened understanding of several processes involved in tumor growth, potentiation, and invasion, resulting in the identification of several attractive molecular targets. This in turn has given rise to antibody-based therapeutics, drug repositioning, and the burgeoning field of RNA interference (RNAi). Secondly, an enhanced understanding of transport phenomena involved in delivery of chemotherapeutics has led to a rethinking and retooling of nanoscale drug carrier designs. Nanoparticle platforms are now incorporating features meant to overcome biological barriers and enhance drug accumulation within tumors, all the while incorporating unique chemistries that enable for controlled release of therapeutic payloads. This review aims to detail the current clinical state of nanoparticle-based therapeutics in breast cancer, as well as highlight several platforms that exemplify the future generation of innovative approaches to chemotherapy in breast cancer.
KW - Breast cancer
KW - Chemotherapy
KW - Liposomes
KW - Nanoparticle drug delivery
KW - Polymer micelles
UR - http://www.scopus.com/inward/record.url?scp=84890875776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890875776&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2013.10.006
DO - 10.1016/j.breast.2013.10.006
M3 - Review article
C2 - 24215984
AN - SCOPUS:84890875776
SN - 0960-9776
VL - 23
SP - 10
EP - 18
JO - Breast
JF - Breast
IS - 1
ER -